Doctors optimistic about new peanut allergy treatment

Doctors optimistic about new peanut allergy treatment

Co-author Stephen Tilles, consulting advisor for Aimmune Therapeutics, said: "We're excited about the potential to help children and adolescents with peanut allergy protect themselves against accidentally eating a food with peanut in it". At the end, when they consumed peanut protein, almost 70% of the kids who'd had the AR101 were able to eat at least 600mg of peanut protein without major symptoms; only 4% in the placebo group could do so.

"Overall household income is only associated with peanut sanitisation in children aged one to nine years", said allergist Sandy Yip, M.D., Major, USAF, lead study author and ACAAI member.

"Until recently there has been nothing to offer peanut allergy suffers other than education around peanut avoidance and recognition and self-treatment of allergic reactions". "The large majority of the study participants tolerated the treatment, and I expect the same will be true of its use in the real world when and if it's approved". Individuals with extreme peanut allergy - characterized by a potentially deadly inflammatory immune response to peanut protein - must remain constantly vigilant in order to avoid even the most minimal accidental exposure, and many must keep an epinephrine injector on hand at all times. AR101 does not eliminate the allergy-children still won't be able to eat their fill of Reese's and Snickers-and patients may have to continue taking maintenance doses throughout their lives.

"It isn't a cure like an antibiotic that makes a bug go away and it's not there anymore", Michael Perkin, a clinical epidemiologist and pediatric allergy consultant at the University of London who wrote a companion editorial to the study, tells Rabin. "These kids can eat enough peanut that parents no longer will have to worry about their teenage daughter kissing someone who's eaten peanut butter".

- Fewer side effects than anticipated - e.g. only six percent dropped out of the study due to gastrointestinal side effects; Also, one-third of patients completed the study with no more than mild side effects along the way.

It involved giving the child small doses of peanut flour and gradually increasing it to boost tolerance over time. Almost 15 percent of people who took AR101 had to take injections of epinephrine to combat severe allergic reactions, and one child needed three injections of an EpiPen. If approved, it could be available by prescription in 2019.

The results, announced Sunday at a conference of the American College of Allergy, Asthma & Immunology in Seattle, may lead to approval of what could be the first oral medication that ameliorates reactions in children with severe peanut allergies.